The US military, through DARPA, is investing $73 million in a new program called RAPIID to develop shelf-stable synthetic blood substitutes. This initiative aims to address the critical shortage of blood for transfusions, which contributes to a significant number of preventable deaths in both military and civilian contexts. The goal is to have deployable dried blood products, including plasma, platelets, and red blood cells, available in the field by 2029. AI
IMPACT This initiative could significantly improve battlefield medical care and reduce preventable deaths by addressing critical blood shortages.
RANK_REASON Significant government funding for a new product development program. [lever_c_demoted from significant: ic=1 ai=0.4]
Read on MIT Technology Review →
- Afghanistan
- Al Anbar Governorate
- Baghdad
- Balad
- DARPA
- Journal of the American College of Surgeons
- Karmah
- Morphine 1-2
- RAPIID
- Robert Murray
- The Journal of the American Medical Association
- Transfusion
- FDA
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →